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Abstract
Background: Prostate cancer is the most common tumor in men. The most commonly used
diagnostic and tumor recurrence marker is Prostate Specific Antigen (PSA). After surgical removal
or radiation treatment, PSA levels drop (PSA nadir) and subsequent elevated or increased PSA
levels are indicative of recurrent disease (PSA recurrence). For clinical follow-up and local care PSA
nadir and recurrence is often hand calculated for patients, which can result in the application of
heterogeneous criteria. For large datasets of prostate cancer patients used in clinical studies PSA
measurements are used as surrogate measures of disease progression. In these datasets a method
to measure PSA recurrence is needed for the subsequent analysis of outcomes data and as such
need to be applied in a uniform and reproducible manner. This method needs to be simple and
reproducible, and based on known aspects of PSA biology.
Methods: We have created a simple Perl-based algorithm for the calculation of post-treatment
PSA outcomes results based on the initial PSA and multiple PSA values obtained after treatment.
The algorithm tracks the post-surgical PSA nadir and if present, subsequent PSA recurrence. Times
to PSA recurrence or recurrence free intervals are supplied in months.
Results:  Use of the algorithm is demonstrated with a sample dataset from prostate cancer
patients. The results are compared with hand-annotated PSA recurrence analysis. The strengths
and limitations are discussed.
Conclusions: The use of this simple PSA algorithm allows for the standardized analysis of PSA
recurrence in large datasets of patients who have undergone treatment for prostate cancer. The
script is freely available, and easily modifiable for desired user parameters and improvements.
Background
Prostate cancer is the most common tumor in men and
accounts for 41% of male new cancer diagnoses and 14%
of cancer deaths. This tumor is predominantly found in
older males and thus most studies of prostate cancer pro-
gression have been confounded by age-related death not
attributable to prostate cancer. For this reason tumor
markers for prostate cancer are of utmost importance in
estimating death from disease. Prostate cancers arise from
the epithelial component of the prostate, a cell that
secretes a protein called Prostate Specific Antigen
(PSA)[1]. This protein is present within prostatic epithe-
lial cells and is secreted in seminal fluid. In addition, pro-
static carcinomas release PSA, which is taken up into the
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blood stream. Thus PSA can be measured in the blood of
patients and has been used as an effective screening
marker for the development of prostate carcinoma in
men[2]. Levels of PSA in the blood drop to less than meas-
urable levels (PSA nadir) after surgical removal of the
prostate (radical prostatectomy) or treatment of prostate
cancer by radiation [3-5]. This reduction of the PSA blood
levels can be tracked over time in men, and the finding of
increasing levels of serum PSA is considered evidence of a
clinical recurrence of prostate cancer (PSA recurrence),
thus triggering additional treatment[3]. These values often
predate the clinical evidence of prostate cancer recurrence
as determined by radiographic or physical examination,
and often are the only initial evidence of prostate tumor
progression[6]. Thus trends or changes in prostate specific
antigen expression over time can be used as a surrogate
marker for prostate cancer related morbidity in clinical
studies. This is of particular value due to the protracted
course of prostate cancer and the current development of
chemotherapeutic, radiotheraputic, cryotheraputic, or
nutritional interventions designed to delay the course of
disease. For these reasons it is very important to be able to
accurately predict and identify trends in the serum PSA
levels. Yet in most clinical studies and local treatment
decisions PSA nadir and recurrence are hand calculated.
This often results in a heterogeneous application of PSA
nadir and recurrence guidelines, providing a confounding
variable for subsequent use of the data in clinical studies.
Thus there is a need for processes that allow for the uni-
form application of PSA nadir and recurrence criteria that
can subsequently be used in clinical studies. Here we
present a simple Perl script that can be used with patient
data for the determination of PSA nadir and recurrence in
men who have been treated for prostate cancer. This algo-
rithm orders the serum PSA values within a data set by
date, determines the rate of decrease and the post-treat-
ment disappearance of serum PSA (PSA nadir) based on
the PSA half-life, and subsequently identifies increases in
serum PSA (PSA recurrence). Timelines are calculated
from the PSA nadir in months recurrence free or months
to PSA recurrence. The clinical standards and practice
guidelines used to determine the rules of the algorithm are
described, but can be freely and easily modified by the
user. The algorithm is demonstrated using a sample pros-
tate cancer dataset.
Methods
The PSA script takes a series of dated PSA values and cal-
culates the PSA drop based on the half-life of PSA in
serum to determine PSA nadir. The time to PSA nadir is
determined based on the "initial PSA", defined as a PSA
value prior to patient treatment, and an estimated PSA
half-life of 2–3 days. If PSA nadir is achieved the script
subsequently calculates the PSA recurrence, if present,
based on sequential rising PSA values and threshold cut-
offs. Requirements for evaluation by the PSA script
include the initial dated PSA value prior to treatment, the
date of initial treatment, and PSA values after radical pros-
tatectomy with their associated dates of testing. With post-
treatment PSA values the script will attempt to determine
a PSA nadir (see below) or post the samples as "recurrence
status unclear." The PSA script uses the initial PSA value
before treatment to calculate the allowed time to PSA
nadir (1 month for PSA values less than 50, 3 months for
PSA values greater than 50, based on a serum PSA half-life
of 2–3 days). If there is an invalid date, defined by a year
before 1900, or a month not 1–12, or the follow-up dates
are after the current date, then the script will output
"Invalid follow-up date found" for that case. If for a par-
ticular case there is no (or an invalid) date of treatment, or
if there is no initial PSA value then the script will output
"unknown". The lack of PSA values within the initial 3
months after treatment will result in the script outputting
"nadir unclear" and then using any additional PSA values
to attempt a calculation of the PSA recurrence status. The
PSA script orders the post-treatment PSA samples by date
and takes the PSA values within 1 or 3 months of the treat-
ment date and examines their decrease to zero (PSA
nadir). These PSA values must decrease to less than 0.4,
but again the user through simple script edits may modify
this. Increasing post-treatment PSA values before the PSA
nadir value is achieved results in the PSA script output
"post prostatectomy elevated PSA." If during the 1 or 3
month post-treatment window the PSA values do not
drop below 0.4, then the script outputs "nadir unclear".
Once this nadir value is achieved the date is then stored as
the "PSA nadir" where no residual prostate cancer is
present. After achieving PSA nadir subroutines are used to
identify subsequent PSA increases over time as an indica-
tion of PSA recurrence. There are many methods for defin-
ing "PSA recurrence", with some authors using any single
value above 0.2[7]. Other authors, in particular the Amer-
ican Society for Theraputic Radiology and Oncology
(ASTRO), have defined three consecutive increases in
serum PSA post-surgery[8]. We have chosen to integrate
both systems, with PSA recurrence in the algorithm
defined as a single PSA value of greater than 0.4, or a PSA
value greater than 0.2 with additional subsequent increas-
ing values. While this has been successful in our hands,
the algorithm is designed such that a few simple coding
changes can allow a person to alter the algorithm to suit
their individual needs. As the PSA levels rise the date of
PSA recurrence is determined as the date of the initial PSA
rise (either the date of the single value of greater than 0.4
or the date of the PSA value greater than 0.2, before the
subsequent rising PSA values) and this date is subtracted
from the date of initial PSA nadir to determine the
months to PSA recurrence. If there was no documented
PSA nadir date then the script uses the initial treatmentBMC Urology 2004, 4 http://www.biomedcentral.com/1471-2490/4/8
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date as the nadir date. These time values are subsequently
recorded for output. Minimum default values used for the
algorithm include a single post-nadir PSA value, other-
wise the output of "nadir achieved, recurrence status
unknown." is provided. Thus this script can be used as a
simple method for calculating PSA recurrence values on
any database that tracks serum PSA levels in patients hav-
ing been treated for prostate cancer.
The script is designed to read data from a flat file in csv for-
mat, and can be used by invoking the following file
PSARecurReadFile.pl InputDataFileName OutputData-
FileName [MaxNumberOfFollowups], where the maxi-
mum number of follow-up PSA values per case can be set
by the user. If the maximum number of follow-up PSA
values is not stated the script will default to a number by
calculating the number from the number of values in the
input file's title line. For example, if the title line is
"init_value, pstm month, pstm year, value A, month A,
year A, value B, month B, year B" 2 (value A and value B)
will be set as the default maximum number of follow-ups
by the script). An output file is provided as additional col-
umns (table 1) with each row representing an individual
case. If these columns already exist in the output file, they
can be overwritten with new data. This is useful when the
script is re-run on a set of existing cases after additional
PSA data has been collected.
Results
Sample outputs analyzed with the PSA recurrence algo-
rithm demonstrate the calculation of PSA recurrence rates
for 30 patients with prostate cancer treated by radical
prostatectomy. An anonymous de-identified sample data-
set of 30 patients with a range of 0 to 21 post-treatment
PSA values per patient were analyzed with the PSA algo-
rithm. Using this dataset (see supplemental file 2) the PSA
script correctly calculated 14 cases that underwent PSA
nadir. Of these cases 8 were without evidence of PSA
recurrence, while 5 underwent PSA recurrence. In 1 case
there was insufficient data to calculate PSA recurrence sta-
tus after achieving PSA nadir. In 10 cases there was insuf-
ficient data to calculate PSA nadir due to a lack of PSA
values within the 1 or 3 month interval after treatment,
but data was available to calculate PSA recurrence status.
The PSA script was not able to calculate the PSA status of
6 cases in the dataset due to missing initial PSA data (3
cases), dates (1 case) of data of any kind (2 cases). The
results obtained from the PSA script was in exact agree-
ment with a hand annotated results calculated by one of
the authors (M.W.D.). In the cases where the PSA script
was not able to provide a definitive result, the author was
able to do no better.
Discussion
The use of the PSA script was able to accurately identify
patients who had undergone PSA nadir, and patients with
subsequent PSA recurrence. In each of these cases the use
of a uniform standard was of great value in the subsequent
analysis of the outcomes data. A specific area worthy of
comment includes the identification of cases with "post-
treatment elevated PSA". In these cases there has been a
failure to achieve PSA nadir, as defined by decreasing PSA
values to less than 0.4 post-prostatectomy. Reasons why a
patient may not undergo PSA nadir include the presence
of residual prostate cancer within the patient. This may be
due to incomplete surgical excision of tumor, spread of
the tumor outside the prostate prior to surgery or radia-
tion treatment. In addition, if residual normal prostate tis-
sue is left within the patient after surgery, this may
account for residual small but elevated PSA levels. Further
evaluation of patients who fail to undergo PSA nadir may
identify the potential roles of these factors in the elevated
PSA values. After PSA nadir, the elevation of PSA values is
indicative of tumor recurrence. The rate at which the PSA
rises, or PSA velocity, has been noted to be different
between local tumor recurrence and the growth of meta-
static disease[9]. This is important as the types of treat-
ment offered to the patients (local radiation or
cryotherapy vs. hormonal/chemotherapy) differ. Further
modifications of this simple script should focus on
improving these measurements if further clinical value is
desired.
Conclusions
Here we have presented a simple Perl script for the evalu-
ation of PSA status in patient datasets. Based on the cur-
rent criteria for PSA nadir and recurrence, the script
provides for the uniform application of PSA nadir and
recurrence criteria. At the same time the script is flexible
enough to allow users to change the criteria (PSA cutoff
values, etc) for specific use interests and studies. It is
hoped that this will facilitate the use of large patient sam-
ples for prostate cancer studies. The Perl script provided
without any restrictions and may be modified for any pur-
pose. It is readily available and is attached to this publica-
tion (appendix). While the script has been used with an
associated Oracle 8 database, the script has been modified
Table 1: Added output columns for each case
psa_recur_status
psa_recur_time
psa_recur_month
psa_recur_year
psa_recur_free
psa_nadir_month
psa_nadir_year
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to be used with an input flat file, and as such does not
need any database.
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Additional File 1
Additional files are provided and include the Perl PSA Recurrence algo-
rithm along with example files of input data and expected output data for 
the optimization of the algorithm by individual users.
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